BACKGROUND

Ten percent to twenty percent of all cardiac operations in the United States are done for valvular heart disease, and aortic valve replacement comprises two-thirds of valve operations. Degenerative aortic stenosis (AS) is the most common form of valvular heart disease in developed countries, and in the U.S., the majority of aortic operations are for AS.¹

The prevalence of AS increases significantly with age. Moderate to severe aortic stenosis is found in only 0.02% of people aged 18 to 44 years, but it increases to 2.8% in people aged 75 years or older.² Patients with AS typically have a long latent phase during which they are asymptomatic,³ but once symptoms develop they have a poor prognosis; with medical therapy alone survival rates are as low as 50% at 2 years and 15% at 5 years.⁴

Traditionally, patients with severe, symptomatic AS are treated with surgical aortic valve replacement (SAVR), which entails sternotomy, cardiopulmonary bypass, excision of the entire diseased valve, and suture of a mechanical or bioprosthetic valve to the aortic annulus. But though SAVR significantly decreases mortality in patients with symptomatic aortic stenosis and it significantly improves their quality of life,⁵ many patients with AS are unfortunately deemed too sick to undergo SAVR and are not offered surgery.⁶ Patients considered too high a risk to undergo SAVR have a much worse prognosis, and less than one third survive beyond 2 years.⁷

THE EMERGENCE OF TAVR

Transcatheter aortic valve replacement (TAVR) has emerged as an alternative to surgery for patients with severe, symptomatic aortic stenosis. The first transcatheter aortic valve implantation was performed by Dr. Alain Cribier in April 2002.⁸ Since then, advances in equipment and technique have led to an exponential increase in the worldwide utilization of TAVR, and by 2013 over 80,000 procedures had been performed.⁹

In TAVR, a bioprosthetic valve is mounted on a catheter, advanced to the aortic annulus, then expanded and deployed inside the native diseased valve [Figures 1 and 2]. Current transcatheter valves consist of a tissue valve made from bovine or porcine pericardium attached to a cylindrical metal cage. In most patients, arterial access is obtained at the common femoral artery and the valve is delivered.
to the aortic annulus through the iliac artery and aorta. However, in patients with inadequate peripheral arteries, alternative routes of delivery include the subclavian artery, the ascending aorta via a small upper sternotomy, or directly through the left ventricular apex via a small lateral thoracotomy.

There are two types of transcatheter valves approved for commercial use in the United States: Balloon Expandable Valves (BEV) and Self Expanding Valves (SEV). The SAPIEN valve, developed by Edwards Lifesciences (Irvine, CA), is a BEV and was the first valve commercially available in the U.S. in November 2011. In the Placement of Aortic Transcatheter Valves (PARTNER) trial, TAVR with the SAPIEN valve resulted in a 25% absolute reduction in mortality at 2 years when compared to medical therapy alone (43.3% for TAVR vs. 68.0% for medical therapy, p < 0.01). When compared to SAVR, TAVR resulted in similar 2-year mortality rates in patients determined to be at high surgical risk (33.9% two year mortality for TAVR vs. 35.0% for SAVR, p = 0.78).

In January 2014, the self-expanding Medtronic CoreValve was approved for TAVR in the United States. The CoreValve US Pivotal Trial demonstrated its efficacy and safety, with a 15.9% absolute reduction in 1 year mortality in patients deemed at extreme risk for SAVR, compared with medical therapy alone (8.4% for TAVR vs. 24.3% for medical therapy, p < 0.01). In addition, in patients deemed merely high risk for surgery, TAVR with the CoreValve resulted in a 4.9% absolute reduction in 1 year mortality compared with SAVR (14.2% for TAVR vs. 19.1% for SAVR, p = 0.04 for superiority). TAVR with both the Sapien and CoreValve resulted in decreased hospital length of stay and improved quality of life at 30 days when compared to SAVR.

**EARLY CHALLENGES AND RECENT ADVANCES**

The early success of TAVR was not without challenges. The first TAVR delivery platforms utilized catheters with an inner diameter of 22 to 24 French (7.3 – 8 mm), which resulted in an initial 30-day rate of peripheral vascular complication of 16.8%. In addition, for patients deemed to have prohibitive surgical risk the 30-day rate of stroke was 5.0% with TAVR vs. 1.1% with only medical therapy. The rate of moderate or greater paravalvular aortic insufficiency at 1 year with TAVR was 4.3-10.5% and the 30-day rate of significant conduction abnormality requiring pacemaker implantation ranged from 3.4% with BEV to 21.6% with SEV.

Fortunately, advances in technology and procedural technique led to significant improvements in clinical outcomes and reductions in complication rates. The original Edwards Sapien valve was modified, and the Sapien XT allowed a smaller delivery catheter and larger valve sizes. It also proved to be an effective therapy for treatment of failed surgical bioprostheses. Recently, the S3 transcatheter valve was released, which can be delivered through a 14 to 16 Fr arterial sheath and accommodates an aortic annulus size from 18 to 28 mm. This development allows a much higher percentage of patients to undergo TAVR via femoral artery access. The S3 has an external cuff that has greatly minimized paravalvular leak (PVL), such that only 2.7% of moderate PVL and no severe PVL are reported. In addition, the rates of disabling stroke and all-cause mortality at 30 days are 0.9% and 2.2%, respectively.

The self-expanding CoreValve has also been modified, giving rise to the Evolut R transcatheter valve. This valve also demonstrates a low rate of PVR at 30 days: 3.4% moderate and 0% severe. More importantly, the valve is completely repositionable and demonstrates a 0% rate of stroke or death at 30 days. The rate of permanent pacemaker implantation with this device has improved, but is still 11.7% at 30 days.
THE NEED FOR FURTHER DEVELOPMENT

Despite the recent advances in TAVR, there are several areas in need of improvement. According to international registries of TAVR, major vascular complications still occur in 2% to 13% of cases\(^1\) and permanent pacemaker implantation is performed after 5% to 50%.\(^{19,20}\) Although there has been a significant reduction in the occurrence of stroke and PVL, continued improvement is needed in these areas as well. Several new devices are in various stages of development and may potentially address some of these issues. The Portico transcatheter valve (St. Jude Medical Inc., St. Paul, Minnesota) and the Lotus transcatheter valve (Boston Scientific Inc., Marlborough, MA) have both received CE approval in Europe and are undergoing evaluation in the U.S. [Figure 5]. Additionally, there are ongoing studies evaluating the safety and efficacy of TAVR in unstudied patient populations including those with moderate surgical risk. The results of these studies could broaden the indications for TAVR.
The Journal of Lancaster General Hospital

Winter 2015

107

The LGH Experience

LGH performed its first TAVR in August 2012. Since that time, the program has grown considerably and the hospital will have performed more than 120 TAVRs at the time of this publication [Figure 6].

During the first year femoral artery access was used in approximately 50% of cases, but with the newest generation of devices the use of femoral artery access is approaching 80%. Utilization of smaller caliber delivery systems has allowed for the use of conscious sedation rather than general anesthesia. More than 10 patients at LGH have undergone TAVR without the use of general anesthesia or endotracheal intubation. These advancements have resulted in a shorter average length of stay that continues to decrease.

The incidence of moderate aortic insufficiency after TAVR at LGH is 2% and there have been no cases of severe aortic insufficiency. These rates are significantly lower than the reported national average of 5% for moderate or greater aortic insufficiency. Two-thirds of patients undergoing TAVR at LGH are discharged directly to home and more than 70% report a large improvement in quality of life. In addition, TAVR outcomes at LGH including mortality rate, stroke, atrial fibrillation, and renal dysfunction have consistently been in the 90th percentile when compared to all other TAVR programs in the United States.

The success of the LGH TAVR program lies in its excellent interdisciplinary collaboration and “team approach.” The TAVR team consists of members from cardiothoracic surgery, interventional cardiology, cardiovascular imaging, congestive heart failure, cardiac anesthesia, critical care and cardiac nursing, physical medicine and rehabilitation, and a dedicated team of specially trained catheterization and surgical nurses and specialists. The TAVR team meets weekly to discuss patient care issues and monthly to discuss program improvement.

Figs. 5. The Lotus transcatheter valve consists of a tissue valve made from bovine pericardium attached to a braided nitinol frame. It can be retrieved and repositioned after complete deployment and functionality. This allows for a complete assessment prior to deciding to permanently release the valve. (Boston Scientific Inc., Marlborough, MA)
CONCLUSION

TAVR has rapidly emerged as a safe and effective alternative for treatment of severe aortic stenosis. It has proven to be superior to medical therapy and at least equivalent to SAVR in patients with a high surgical risk. While several limitations still exist, rapid advancements in this technology are leading to continued improvements in clinical outcomes and decreased complication rates.

The LGH TAVR program has grown rapidly over the past few years and is becoming a high-volume center of excellence. With a focus on collaboration, innovation, and teamwork, the LGH TAVR team is delivering superlative clinical outcomes to the patients of southeast Pennsylvania.

James E. Harvey, M.D., M.Sc.
Medical Director, Structural Heart Intervention
Interventional Cardiology
The Heart Group of Lancaster General Health
217 Harrisburg Ave.
Lancaster, PA 17603
717-544-8300

Sherri S. Delgado, M.S.N., C.R.N.P., C.C.R.N.
LGH Structural Heart Coordinator
The Heart Group of Lancaster General Health
217 Harrisburg Ave.
Lancaster, PA 17603
717-544-8300
SSDelgad@lghealth.org
REFERENCES


